目的 探討蒲元和胃膠囊聯(lián)合莫沙必利和泮托拉唑治療反流性食管炎的臨床療效。方法 選取安陽(yáng)市人民醫(yī)院2013年10月—2016年10月收治的102例反流性食管炎患者，隨機(jī)分為對(duì)照組和治療組，每組各51例。對(duì)照組患者飯前口服枸櫞酸莫沙必利片，1片/次，3次/d；同時(shí)早晨空腹口服泮托拉唑鈉腸溶片，1片/次，1次/d。治療組患者在對(duì)照組的基礎(chǔ)上于飯后1 h口服蒲元和胃膠囊，4粒/次，3次/d。兩組患者均連續(xù)治療6周。評(píng)價(jià)兩組患者臨床療效，比較治療前后兩組患者生活質(zhì)量和臨床癥狀評(píng)分。結(jié)果 治療后，對(duì)照組的總有效率為84.31%，顯著低于治療組的96.08%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。治療后，兩組患者各項(xiàng)生活質(zhì)量評(píng)分均較治療前明顯升高，臨床癥狀評(píng)分均顯著降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）；且治療組患者生活質(zhì)量和臨床癥狀評(píng)分改善程度顯著優(yōu)于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。結(jié)論 蒲元和胃膠囊聯(lián)合莫沙必利和泮托拉唑治療反流性食管炎療效顯著，安全性較高，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To evaluate the clinical efficacy of Puyuan Hewei Capsules combined with mosapride and pantoprazole in treatment of reflux esophagitis. Methods Patients (102 cases) with reflux esophagitis in the People's Hospital of Anyang from October 2013 to October 2016 were randomly divided into control and treatment groups, and each group had 51 cases. Patients in the control group were po administered with Mosapride Citrate Tablets before meals, 1 tablet/time, three times daily. And they were fasting po administered with Pantoprazole sodium Enteric-Coated Tablets at the same time, 1 tablet/time, once daily. Patients in the treatment group were po administered with Puyuan Hewei Capsules on the basis of the control group 1 h after meals, 4 grains/time, three times daily. Patients in two groups were treated for 6 weeks. After treatment, the clinical efficacy was evaluated, and the quality of life and clinical symptoms scores in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control was 84.31%, which was significantly lower than 96.08% in the treatment group, and there were differences between two groups (P < 0.05). After treatment, the quality of life score in two groups significantly increased, and clinical symptoms score significantly decreased, the difference was statistically significant in the same group (P < 0.05). And the quality of life and clinical symptoms scores in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Puyuan Hewei Capsules combined with mosapride and pantoprazole has significant clinical efficacy in treatment of reflux esophagitis with good safety, which has a certain clinical application value.